Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report

Abacus Global Management (ABL) is facing significant headwinds as its stock price has declined over 36% in the past month following critical reports from Morpheus Research, a group with ties to Hindenburg Research, alleging accounting manipulation and undisclosed related-party transactions. Despite Abacus's denials and a $20 million share repurchase program, investor confidence remains low, prompting law firm Hagens Berman to launch an investigation and solicit information from affected shareholders and whistleblowers.

Analysis

Abacus Global Management (NASDAQ: ABL) is experiencing a severe crisis of investor confidence, evidenced by its stock plummeting over 36% in the past month to trade near its 52-week low. This precipitous decline is directly attributable to a series of critical reports from Morpheus Research, a new investigative firm staffed by analysts formerly with Hindenburg Research, renowned for exposing alleged corporate misconduct at companies like Nikola Corporation and Clover Health. Morpheus's initial report on June 4, 2025, accused Abacus of manipulating its life settlements portfolio through aggressive mark-to-model accounting and questionable life expectancy estimates, leading to claims of inflated asset values and "fake revenue," which caused an immediate 20% single-day stock drop. A subsequent report on June 12 intensified these concerns, alleging inconsistencies in Abacus's rebuttal with its own SEC filings, introducing new claims of undisclosed related-party transactions and "Carlisle Round-Tripping Policies," and questioning the independence of Lewis & Ellis, the actuarial firm Abacus retained for a balance sheet review. Despite Abacus's public denials and the authorization of a $20 million share repurchase program to be executed over 18 months, these measures have failed to stem the stock's slide. The situation is further compounded by law firm Hagens Berman launching its own investigation into potential misrepresentation of asset valuations and the independence of Lewis & Ellis, actively seeking information from affected shareholders and whistleblowers. The "extremely negative" sentiment score of -0.85 and high market impact score of 0.85, coupled with a specific -0.9 sentiment for ABL, underscore the gravity of the situation, with an InvestingPro insight also suggesting ABL was not identified as a top undervalued stock.

Key Decisions for Investors

• Extreme caution is warranted regarding Abacus Global Management shares due to severe allegations of accounting manipulation, a Hindenburg-linked short-seller campaign, a significant stock price collapse, and an active legal investigation by Hagens Berman.
• Investors should closely monitor for further reports from Morpheus Research, updates on Hagens Berman's investigation, the findings of the Lewis & Ellis independent review when published, and any substantive responses from Abacus management addressing the core allegations.
• The announced $20 million share repurchase program should be viewed critically, as its ability to counteract the substantial negative sentiment and address the fundamental concerns raised about the company's accounting practices and asset valuations appears limited thus far.
• The prevailing "extremely negative" sentiment and external indications that ABL may not be undervalued suggest potential for continued share price volatility and downside risk, warranting a reassessment of any existing positions.